Avalo Therapeutics (AVTX) Stock Price Target 2026

The average analyst price target for Avalo Therapeutics is $35.57, 404.5% above the current price. Of 15 analysts, 13 rate it Buy and 2 Hold. Targets range from $10 to $60. The latest change came on Oct 23, 2026, when Guggenheim downgraded Avalo Therapeutics from Buy to Neutral.

The Average Analyst Price Target for Avalo Therapeutics is $35.57.

Price Target Range — 10 Quarters

Analyst Consensus — 15 Analysts

1S.Buy

12Buy

2Hold

Consensus RatingBuy# Analysts15Avg. Consensus PT$35.57Upside to Avg. PT+404.5%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Avalo Therapeutics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 23, 2026	Guggenheim	Yatin Suneja	Downgrade	Buy→Neutral	—
Oct 23, 2026	Wedbush	Robert Driscoll	PT Cut	Outperform	$34→$22
Oct 23, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Downgrade	Buy→Neutral	—
Oct 23, 2026	BTIG	Julian Harrison	PT Cut	Buy	$58→$10
Aug 7, 2026	Guggenheim	Yatin Suneja	PT Cut	Buy	$50→$48
Aug 7, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$35→$30
Jul 6, 2026	Leerink Partners	Thomas Smith	Initiate	Outperform	$38
Jun 16, 2026	BTIG	Julian Harrison	Maintained	Buy	$58
Jun 12, 2026	B of A Securities	Alec Stranahan	Initiate	Buy	$35
May 14, 2026	Citizens	Jason N. Butler	PT Cut	Market Outperform	$62→$55
May 14, 2026	Wedbush	Robert Driscoll	PT Cut	Outperform	$40→$34
May 14, 2026	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$39→$45
May 14, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$40→$35
May 11, 2026	Piper Sandler	Yasmeen Rahimi	PT Raise	Overweight	$48→$60
May 6, 2026	Citizens	Jason N. Butler	PT Raise	Market Outperform	$52→$62
May 6, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$29→$40
May 6, 2026	BTIG	Julian Harrison	PT Raise	Buy	$40→$58
Apr 13, 2026	BTIG	Julian Harrison	Maintained	Buy	$40
Apr 9, 2026	Wolfe Research	Andy Chen	Initiate	Outperform	$48
Apr 6, 2026	Citizens	Jason Butler	Initiate	Market Outperform	$52